Triton to sell Blitz LuxCo Sarl, the holding company of the Bormioli Pharma
Group

Issuer: Triton Beratungsgesellschaft GmbH / Key word(s): Mergers &
Acquisitions
Triton to sell Blitz LuxCo Sarl, the holding company of the Bormioli Pharma
Group

23.05.2024 / 07:32 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Triton to sell Blitz LuxCo Sarl, the holding company of the Bormioli Pharma
Group

Luxembourg, 23 May 2024 - Funds advised by Triton ("Triton"), alongside
co-investors, have signed an agreement to sell Blitz LuxCo Sarl, the holding
company of Bormioli Pharma Group ("Bormioli" or "the company"), a leading
producer of pharmaceutical packaging, to Gerresheimer, an innovative systems
and solutions provider and global partner for the pharma, biotech, and
cosmetics industries. The transaction is subject to regulatory approvals and
expected to close in the fourth quarter this year.

Bormioli was acquired by Triton in 2017 via a corporate carveout, having
been identified as a future winner benefitting from increasing demand for
sustainable packaging while providing drug stability and patient safety. The
company has since been transformed into an important player in pharma
packaging, present in over 100 countries, has approx. 1,500 employees with
sales of over EUR 370 million.

Triton helped Bormioli to reach its potential by bolstering its management
team; reshaping its organisational and operational structure; expanding and
upgrading the company's manufacturing base with state-of-the-art technology;
establishing one of the first pharma packaging solutions based upon recycled
materials; and integrating four strategic acquisitions that bolstered its
product portfolio and geographical presence.

Moritz Gudenus, Investment Advisory Professional at Triton, said: "We would
like to sincerely thank Bormioli's entire team for their hard work and
commitment in unlocking the company's potential. Our investment in Bormioli
is another example of Triton's approach of backing future winners in our
core sectors and applying our operational approach to helping them reach
their full potential. We believe that Gerresheimer is a great strategic fit
to continue Bormioli's success story."

Andrea Lodetti, CEO of Bormioli Pharma Group, adds: "With the support of
Triton, we were able to build out our positions across pharma packaging,
with one-stop-shop capabilities in terms of technology as well as product
offering. We thank the Triton team for their support and look forward to our
next chapter of growth with Gerresheimer."

BNP Paribas and Goldman Sachs International acted as M&A financial advisors.

Press Contact

Triton

Anja Schlenstedt

Email: media@triton-partners.com

About Triton

Founded in 1997 and owned by its partners, Triton is a leading European
mid-market sector-specialist investor. Triton focuses on investing in
businesses that provide mission critical goods and services in its three
core sectors of Business Services, Industrial Tech, and Healthcare.

Triton has over 200 investment professionals across 11 offices and invests
through three complementary "All Weather" strategies: Mid-Market Private
Equity, Smaller Mid-Cap Private Equity, and Opportunistic Credit.

For further information: www.triton-partners.com

About Bormioli Pharma

Bormioli Pharma works closely with the pharmaceutical industry and all
companies that are working towards the future of healthcare globally. As a
world-renowned player in the packaging industry, the company serves the
pharmaceutical and biopharmaceutical markets with complete solutions,
including glass and plastic bottles, plastic and aluminium closures and
accessories. Bormioli Pharma's wide product ranges are designed and
manufactured with a focus on innovation and addressing ever-growing
sustainability issues. Moreover, each product is specifically conceived for
the destination market thanks to an accurate portfolio segmentation.
Bormioli Pharma has a global presence in over 100 countries, with around
1,500 employees and 9 plants across Europe specialized in the production of
glass and plastic packaging. In 2023, the company sold more than 8 billion
pieces. As a partner to the pharmaceutical industry, Bormioli Pharma invests
and innovates with a single goal: making health a positive practice,
available to everyone, kind to the planet.

For further information: www.bormiolipharma.com/en

About Gerresheimer

Gerresheimer is an innovative systems and solutions provider and a global
partner for the pharma, biotech, and cosmetic industries. The company offers
a comprehensive portfolio of pharmaceutical containment solutions, drug
delivery systems and medical devices as well as solutions for the health
industry. The product range includes digital solutions for therapy support,
medication pumps, syringes, pens, auto-injectors, and inhalers as well as
vials, ampoules, tablet containers, dropper bottles, other bottles and more.
Gerresheimer ensures the safe delivery and reliable administration of drugs
to the patient. With 35 production sites in 16 countries in Europe, America
and Asia, Gerresheimer has a global presence and produces locally for
regional markets. With around 12,000 employees, the company generated
revenues of around EUR2bn in 2023. Gerresheimer AG is listed in the MDAX on
the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).

www.gerresheimer.com


---------------------------------------------------------------------------

Dissemination of a Corporate News, transmitted by EQS News - a service of
EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------